Skip to main content

CYTK Cytokinetics, Incorporated

Healthcare

quality needs a look, discounted valuation.

Quality
Weak
Valuation
Cheaper
Key signals
Filed revenue acceleration
69.92
69.92 Close (USD) Loading candles…

Is Cytokinetics, Incorporated a buy? Fundamentals and valuation first

  • Quality is weaker than peers. Operating margin is only around the 6th percentile. TTM ROE is about 100.4%.

  • Valuation is cheaper than most peers. TTM P/E is in the 17th percentile, lower than most liquid US common stocks.

  • Recent volatility is moderate. 60-day annualized volatility is near the 39th percentile. Average 20-day dollar volume is about $128.2M.

  • Signals are active now. Filed revenue acceleration currently holds; the tables below show what followed in this stock’s own history.

Watchlist

This page refreshes daily after the close. Add Cytokinetics, Incorporated to your watchlist to track signal changes on your next visit.

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Filed revenue acceleration

Active · now 450.60360079092516%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

14 historical occurrences (since 2019-03-07)
Average forward return after Filed revenue acceleration。20-day: Win 57.1%, Sample 14, Median +1.5%, Excess +4.78%, Beat mkt rate 42.9%；60-day: Win 78.6%, Sample 14, Median +15.92%, Excess +13.56%, Beat mkt rate 64.3%；120-day: Win 69.2%, Sample 13, Median +44.24%, Excess +27.84%, Beat mkt rate 61.5%

120 days after: historical avg +35.41%

20-day +7.21%
60-day +17.36%
120-day +35.41%
20-day
60-day
120-day
Win
57.1%
78.6%
69.2%
Sample
14
14
13
Median
+1.5%
+15.92%
+44.24%
Excess
+4.78%
+13.56%
+27.84%
Beat mkt rate
42.9%
64.3%
61.5%

Over 13 occurrences, 120-day forward avg gained 35.41%, beat the market by 27.84 pts; win rate 69.2%.

Market-wide momentum baseline

Across 98,498 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.12%, a 57.9% positive-return rate, and +2.77 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

21 times historically; 60-day forward avg +3.06%, win rate 57.1%, beating the market by +1.05 pts on average.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

28 times historically; 60-day forward avg +9.96%, win rate 77.8%, beating the market by +8.2 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

16 times historically; 60-day forward avg +15.48%, win rate 76.9%, beating the market by +11.55 pts on average.

Continue researching Cytokinetics, Incorporated with the evidence above.

Continue in Studio ↗

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.